Abstract
To the Editor: Although the pathogenesis of allergic contact dermatitis (ACD) has been classically thought to be driven predominantly by Th1, its complex pathophysiology is now accepted to include Th2, Th17, and Th22 pathways.1 Due to the involvement of the Th2 pathway and concomitant ACD diagnosis in many patients with atopic dermatitis (AD), numerous reports have recently described the use of dupilumab in patients with ACD.2 A systematic review was conducted to better understand the effect of dupilumab on ACD and patch testing results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
